- Stocks
- Healthcare
- NASDAQ: LJPC

Price (delayed)

$4.71

Market cap

$129.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.59

Enterprise value

$91.1M

The revenue has soared by 128% YoY and by 79% from the previous quarter

The debt has plunged by 98% YoY and by 9% from the previous quarter

LJPC's quick ratio has soared by 66% since the previous quarter but it is down by 28% year-on-year

La Jolla Pharmaceutical's equity has increased by 18% from the previous quarter but it has decreased by 17% YoY

LJPC's gross margin is down by 14% year-on-year

What are the main financial stats of LJPC

Market
Valuations
Earnings

Shares outstanding

27.45M

Market cap

$129.28M

Enterprise value

$91.1M

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

2.15

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1.52

Revenue

$59.97M

EBIT

-$6.14M

EBITDA

-$2.65M

Free cash flow

-$6.29M

Per share
Balance sheet
Liquidity

EPS

-$0.59

Free cash flow per share

-$0.23

Book value per share

-$2.64

Revenue per share

$2.19

TBVPS

$2

Total assets

$89.59M

Total liabilities

$161.91M

Debt

$490,000

Equity

-$72.32M

Working capital

$42.56M

Debt to equity

-0.01

Current ratio

4.63

Quick ratio

3.66

Net debt/EBITDA

14.39

Margins
Efficiency
Dividend

EBITDA margin

-4.4%

Gross margin

77.6%

Net margin

-27.4%

Operating margin

-13.1%

Return on assets

-18.8%

Return on equity

N/A

Return on invested capital

-44.5%

Return on capital employed

-7.9%

Return on sales

-10.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the La Jolla Pharmaceutical stock price performed over time

Intraday

-3.88%

1 week

-8.54%

1 month

25.27%

1 year

-14.83%

YTD

21.39%

QTD

11.08%

How have La Jolla Pharmaceutical's revenue and profit performed over time

Revenue

$59.97M

Gross profit

$46.53M

Operating income

-$7.89M

Net income

-$16.41M

Gross margin

77.6%

Net margin

-27.4%

The revenue has soared by 128% YoY and by 79% from the previous quarter

LJPC's gross profit has soared by 97% YoY and by 82% from the previous quarter

LJPC's operating margin has soared by 96% YoY and by 88% QoQ

The net margin has soared by 92% YoY and by 77% from the previous quarter

What is La Jolla Pharmaceutical's growth rate over time

What is La Jolla Pharmaceutical stock price valuation

P/E

N/A

P/B

N/A

P/S

2.15

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1.52

La Jolla Pharmaceutical's EPS has soared by 83% YoY and by 59% from the previous quarter

The revenue has soared by 128% YoY and by 79% from the previous quarter

The stock's P/S is 100% below its 5-year quarterly average of 949.0 and 35% below its last 4 quarters average of 3.3

How efficient is La Jolla Pharmaceutical business performance

La Jolla Pharmaceutical's ROS has soared by 97% YoY and by 88% from the previous quarter

La Jolla Pharmaceutical's return on invested capital has surged by 74% YoY and by 62% QoQ

The return on assets has surged by 71% year-on-year and by 55% since the previous quarter

What is LJPC's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for LJPC.

How did La Jolla Pharmaceutical financials performed over time

The total assets is 45% less than the total liabilities

LJPC's quick ratio has soared by 66% since the previous quarter but it is down by 28% year-on-year

The company's current ratio has surged by 57% QoQ but it fell by 14% YoY

The debt is 101% more than the equity

The debt has plunged by 98% YoY and by 9% from the previous quarter

La Jolla Pharmaceutical's debt to equity has surged by 98% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.